NAPG

Across TCGA pan-cancer cohorts, NAPG Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NAPG data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher NAPG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NAPG expression acts as an unfavorable survival marker.

STAD, COAD, and UCS are the cancer types where NAPG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.003	0.667	<.001	18	view →
COAD	DFS	Median	All	0.271	0.692	.006	15	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

NAPG–STAD (OS)

Open the STAD breakdown →